Cargando…
Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects
Keverprazan, a novel potassium‐competitive acid blocker, was approved for treating acid‐related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and pharmacodynamics (PDs) of multiple doses of keverprazan. This was a randomized, positive‐/placebo‐controlled, phase Ic trial. T...
Autores principales: | Zhou, Sufeng, Xie, Lijun, Zhou, Chen, Wang, Lu, Chen, Juan, Ding, Sijia, Zhu, Bei, Su, Mei, Shao, Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582672/ https://www.ncbi.nlm.nih.gov/pubmed/37533172 http://dx.doi.org/10.1111/cts.13598 |
Ejemplares similares
-
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
por: Jenkins, H, et al.
Publicado: (2015) -
Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects
por: Oh, JungJin, et al.
Publicado: (2023) -
Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects
por: Lee, Woo Yul, et al.
Publicado: (2020) -
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects
por: Li, Zhaoyang, et al.
Publicado: (2020) -
The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan
por: Mulford, Darcy J., et al.
Publicado: (2021)